Bausch & Lomb CORP

Bausch + Lomb Corporation announced robust second-quarter 2026 results, with revenue up 9% and full-year guidance increased.

Bausch + Lomb Corporation shareholders re-elected all director nominees and approved executive compensation at the Annual Meeting on May 20, 2026, also appointing PricewaterhouseCoopers LLP as auditor.

Bausch + Lomb Corporation reported strong first-quarter 2026 results, with revenue up 9% and a significant improvement in operating income, leading to a raised full-year guidance.

Bausch + Lomb Corporation has successfully refinanced its outstanding Term B loans, securing a new $2.8 billion tranche with reduced interest margins and an extended maturity for a portion of its debt.

Bausch + Lomb Corporation announced the appointment of recently added directors, Dr. Eduardo C. Alfonso and Steven H. Collis, to key board committees, effective January 1, 2026.

Bausch + Lomb Corporation announced the appointment of Dr. Eduardo C. Alfonso and Steven H. Collis to its board of directors, effective January 1, 2026.

Bausch + Lomb Corporation announced a significant increase in revenues and operating income for the second quarter of 2026, driven by strong performance across its Vision Care, Pharmaceuticals, and Surgical segments.

Bausch + Lomb Corporation announced its first quarter 2026 financial results, reporting a 9% increase in total revenues to $1.244 billion, driven by favorable foreign currency impacts, increased pricing, and higher volumes across key segments.

Bausch + Lomb reported a 7% increase in Q3 revenues to $1.28 billion, but net loss widened to $28 million, impacted by higher expenses and a voluntary IOL recall.

Bausch + Lomb announced a 5% increase in second-quarter revenues to $1.278 billion, driven by volume growth and acquisitions, despite an operating loss of $11 million and increased interest expenses following a significant debt refinancing.

Bausch + Lomb saw a revenue increase in Q1 2025, but a voluntary recall and increased expenses led to a larger net loss compared to the same period last year.

Bausch + Lomb's Q3 2024 results show a significant revenue increase driven by recent acquisitions and higher sales volumes across its segments.

Bausch + Lomb's 2024 annual report reveals a 16% revenue increase, driven by volume growth and strategic acquisitions, while the company continues to evaluate options for separating from Bausch Health.

Bausch + Lomb's 2023 10-K filing reveals a year of strategic acquisitions, revenue growth, and ongoing efforts to manage economic headwinds and prepare for future separation from Bausch Health Companies Inc.

Luc Bonnefoy, President of Surgical at Bausch & Lomb Corp, reported a transaction involving common shares on June 12, 2026.

Director Andrew C. von Eschenbach received an annual grant of 15,842 restricted share units in Bausch + Lomb Corporation.

Director Thomas W. Ross Sr. acquired 15,842 restricted share units as part of an annual compensation grant.

Director Russel C. Robertson acquired 15,842 common shares of Bausch + Lomb Corporation via an annual RSU grant.

Director John Paulson acquired 15,842 common shares of Bausch + Lomb Corporation through an annual RSU grant.

Director Karen Ling acquired 15,842 restricted share units of Bausch + Lomb Corporation as part of an annual director compensation grant.

Bausch + Lomb updates its proxy statement to reflect agreements between its majority shareholder, Bausch Health Companies Inc., and certain shareholder groups regarding board representation and voting.

Bausch + Lomb achieved impressive results in 2024, marked by 16% reported revenue growth and a 17% constant currency revenue increase, driven by successful product launches and leadership in key categories.

Bausch + Lomb Corporation will hold its 2024 Annual Meeting of Shareholders virtually on May 29, 2024, to vote on director elections, executive compensation, an incentive plan amendment, and auditor appointment.